- Home
- CIFR vs RDY Comparison
CIFR vs RDY Comparison
Compare CIFR & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIFR | RDY |
|---|---|---|
| Founded | 2021 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 9.9B |
| IPO Year | 2020 | 2001 |
Fundamental Metrics
Financial Performance| Metric | CIFR | RDY |
|---|---|---|
| Price | $15.15 | $12.23 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 22 | 5 |
| Target Price | ★ $30.93 | $13.30 |
| AVG Volume (30 Days) | ★ 29.5M | 2.8M |
| Earning Date | 11-02-2026 | 10-23-2026 |
| Dividend Yield | N/A | ★ 0.52% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $223,942,000.00 | N/A |
| Revenue This Year | N/A | $4.78 |
| Revenue Next Year | $290.65 | $11.59 |
| P/E Ratio | ★ N/A | $18.67 |
| Revenue Growth | ★ 48.04 | N/A |
| 52 Week Low | $11.72 | $11.36 |
| 52 Week High | $30.14 | $15.67 |
Technical Indicators
Market Signals| Indicator | CIFR | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 40.73 | 49.66 |
| Support Level | $14.50 | $12.09 |
| Resistance Level | $17.69 | $12.48 |
| Average True Range (ATR) | 1.13 | 0.23 |
| MACD | -0.18 | 0.03 |
| Stochastic Oscillator | 7.46 | 50.00 |
Price Performance
Historical ComparisonAbout CIFR Cipher Mining Inc.
Cipher Digital Inc is focused on high-performance computing (HPC) data center development and operations. It is engaged in developing and operating data centers designed for HPC workloads. Its operations include managing power assets and capital allocation in response to market conditions and demand for AI-related computing capacity.
About RDY Dr. Reddy's Laboratories Ltd
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.